Molecular Design, Expression and Evaluation of PASylated Human Recombinant Erythropoietin with Enhanced Functional Properties

High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation

(2014) Claudia T Mendler et al.   mAbs

Pharmacokinetics and Pharmacodynamics of Recombinant Human EPO-Fc Fusion Protein In Vivo

(2013) Xunlong Shi et al.   PLoS One

PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins

(2013) M. Schlapschy et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Strategies for extended serum half-life of protein therapeutics

(2011) Roland E Kontermann   CURRENT OPINION IN BIOTECHNOLOGY

Design, modeling, and expression of erythropoietin cysteine analogs in Pichia pastoris: Improvement of mean residence times and in vivo activities through cysteine-specific PEGylation

(2011) Ahmad Maleki et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Glycosylation-modified erythropoietin with improved half-life and biological activity

(2010) Dongmei Su et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: A comparison with glycosylated erythropoietin

(2010) Yin-Jue Wang et al.   JOURNAL OF CONTROLLED RELEASE

Regulation of erythropoietin production

(2010) Wolfgang Jelkmann   JOURNAL OF PHYSIOLOGY-LONDON

Strategies to Extend Plasma Half-Lives of Recombinant Antibodies

(2009) Roland E. Kontermann   BIODRUGS

Production and characterization of long-acting recombinant human albumin–EPO fusion protein expressed in CHO cell

(2009) Chan-Hi Joung et al.   PROTEIN EXPRESSION AND PURIFICATION

The Pharmacology of PEGylation: Balancing PD with PK to Generate Novel Therapeutics

(2008) C.Simone Fishburn   JOURNAL OF PHARMACEUTICAL SCIENCES